D3S-001 is under clinical development by D3 Bio and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how D3S-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D3S-001 is under development for the treatment of solid tumor, unspecified immunological disorders, non-small cell lung cancer, pancreatic cancer and colorectal cancer. It is administered through oral route. It acts by targeting KRAS G12C mutations.
D3 Bio overview
D3 Bio provides healthcare-related services. It is headquartered in Zhejiang, China.
For a complete picture of D3S-001’s drug-specific PTSR and LoA scores, buy the report here.